Diroximel fumarate (relapsing-remitting multiple sclerosis)


  • Active Substance: Diroximel fumarate
  • Name: Vumerity®
  • Therapeutic area: Multiple sclerosis
  • Pharmaceutical company: Biogen GmbH

Time table:

  • Start: 01.01.2022
  • Publication of assessment: 01.04.2022
  • End of public hearing: 22.04.2022
  • Final decision by G-BA: Temporarily suspended

Comparative therapy:

  • Interferon β-1a or interferon β-1b or glatiramer acetate or dimethyl fumarate or teriflunomide or ocrelizumab, taking into account the drugs' approval